Phase 1Active, not recruiting
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Phase I Study of the Administration of Multi-Virus-Specific Cytotoxic T Lymphocytes Expressing CD19 Chimeric Receptors for Prophylaxis or Therapy of Relapse of CD19 Positive Malignancies Post Hematopoietic Stem Cell Transplantation
- Sponsor
- Baylor College of Medicine (Academic or other)
- Enrolment
- 68 planned
- Conditions
- Acute Lymphoblastic Leukemia (ALL); Chronic Lymphocytic Leukemia (CLL); Non Hodgkin's Lymphoma
- Interventions
- CD19CAR/virus specific T cells; Benadryl and Tylenol
- Ages
- children, adults, older adults
- Registry
- NCT00840853
Full record on ClinicalTrials.gov
From the registry
Subjects are having a bone marrow or SCT for either a type of cancer of the blood called Leukemia or a cancer of the lymph nodes called non- Hodgkin's Lymphoma. Although a transplant can cure leukemia or lymphoma, some people will relapse. In those who relapse, current treatment cures only a very small percentage. Although giving patients a dose of donor immune cells before relapse can prevent relapse of the leukemia or lymphoma, DLI can also cause a serious complication called graft versus host disease (GVHD). This is a gene transfer research study using special immune cells which are specific for these cancer cells. The body has different ways of fighting infection and disease. This study combines 2 of those ways, antibodies and T cells. T cells (CTLs or cytotoxic T cells) are infection-fighting blood cells that can kill cells, including tumor cells. Antibodies and T cells have been used to treat patients with cancers; they have shown promise, but haven't been strong enough to cure most patients. The antibody used in this study is called anti-CD19. This antibody sticks to…
Primary outcomes
- Number of dose limiting toxicities
History
Study completion expected
Last registry update
Primary completion
Started
Registered